Top Markets
Coin of the day
Lysogene S.A. Lysogene S.A.

Lysogene S.A.

LYS
Rang in Aktien #36618
Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy,... Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders. Its development pipeline includes LYS-SAF302, which is currently undergoing Phase II/III clinical trials for mucopolysaccharidosis type IIIA (MPS IIIA). Another promising candidate, LYS-GM101, is in Phase I/II development, targeting GM1 gangliosidosis. The company has also forged a research alliance with the Weizmann Institute of Science to pioneer novel adeno-associated virus (AAV) gene therapy approaches for conditions such as neuronopathic Gaucher disease, Parkinson's disease, and other related illnesses. Lysogene S.A. was established in 2009 and is headquartered in Neuilly-sur-Seine, France.
Aktienkurs
$0.30221445
Zuletzt synchronisiert: 2023-05-22
Marktkapitalisierung
$2.49M
Veränderung (1 Tag)
-0.10%
Veränderung (1 Jahr)
0.00%
Land
FR
Handel Lysogene S.A. (LYS)

Kategorie

Dividendenrendite-Verlauf für Lysogene S.A. (LYS)
Dividendenrendite (TTM) von Lysogene S.A. (Aktienkürzel: LYS) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Lysogene S.A. (LYS) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber